Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review. [electronic resource]
Producer: 20141217Description: 537-45 p. digitalISSN:- 1473-4877
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- therapeutic use
- Carcinoma, Renal Cell -- drug therapy
- Disease-Free Survival
- Everolimus
- Female
- Humans
- Kidney Neoplasms -- drug therapy
- Male
- Middle Aged
- Niacinamide -- analogs & derivatives
- Phenylurea Compounds -- therapeutic use
- Proportional Hazards Models
- Protein Kinase Inhibitors -- therapeutic use
- Retrospective Studies
- Sirolimus -- analogs & derivatives
- Sorafenib
- Treatment Outcome
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.